Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines

Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents

(2011) Ali K. Abu-Alfa   ADVANCES IN CHRONIC KIDNEY DISEASE

Risk of Nephrogenic Systemic Fibrosis in Liver Transplantation Patients

(2011) Daniel S. Chow et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark

(2011) T.R. Elmholdt et al.   BRITISH JOURNAL OF DERMATOLOGY

Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis

(2011) P. Marckmann et al.   CLINICAL NEPHROLOGY

Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines

(2011) Fulvio Stacul et al.   EUROPEAN RADIOLOGY

Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendations

(2011) Michael Girardi et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Screening Patients to Assess Renal Function Before Administering Gadolinium Chelates: Assessment of the Choyke Questionnaire

(2010) Brena F. Sena et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases

(2010) Y Tsushima et al.   BRITISH JOURNAL OF RADIOLOGY

Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far?

(2010) Sameh K. Morcos   EUROPEAN RADIOLOGY

The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice

(2010) Thaddeus J. Wadas et al.   MAGNETIC RESONANCE IN MEDICINE

Nephrogenic systemic fibrosis and contrast medium-induced nephropathy: a choice between the devil and the deep blue sea for patients with reduced renal function?

(2009) K. Lind Ramskov et al.   ACTA RADIOLOGICA

Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease

(2009) Gertraud Heinz-Peer et al.   EUROPEAN JOURNAL OF RADIOLOGY

Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents

(2009) Hubertus Pietsch et al.   EUROPEAN RADIOLOGY

High Prevalence of Nephrogenic Systemic Fibrosis in Chronic Renal Failure Patients Exposed to Gadodiamide, a Gadolinium-Containing Magnetic Resonance Contrast Agent

(2009) Casper Rydahl et al.   INVESTIGATIVE RADIOLOGY

Nephrogenic systemic fibrosis versus contrast-induced nephropathy: Risks and benefits of contrast-enhanced MR and CT in renally impaired patients

(2009) Diego R. Martin et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Nephrogenic Systemic Fibrosis: History and Epidemiology

(2009) Henrik S. Thomsen   RADIOLOGIC CLINICS OF NORTH AMERICA

Involvement of Gadolinium Chelates in the Mechanism of Nephrogenic Systemic Fibrosis: An Update

(2009) Jean-Marc Idée et al.   RADIOLOGIC CLINICS OF NORTH AMERICA

Nephrogenic Systemic Fibrosis: Clinical Picture and Treatment

(2009) Peter Marckmann et al.   RADIOLOGIC CLINICS OF NORTH AMERICA

Chronic inflammation and accelerated atherosclerosis as important cofactors in nephrogenic systemic fibrosis following intravenous gadolinium exposure

(2008) Scott O. Grebe et al.   Clinical and Experimental Nephrology

Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: A summary of the medical literature reporting

(2008) Dale R. Broome   EUROPEAN JOURNAL OF RADIOLOGY

Extracellular Gd-CA: Differences in prevalence of NSF

(2008) Henrik S. Thomsen et al.   EUROPEAN JOURNAL OF RADIOLOGY

Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions

(2008) Martin A. Sieber et al.   EUROPEAN RADIOLOGY

Is NSF only the tip of the “gadolinium toxicity” iceberg?

(2008) Henrik S. Thomsen   JOURNAL OF MAGNETIC RESONANCE IMAGING

Gadodiamide contrast agent ‘activates’ fibroblasts: a possible cause of nephrogenic systemic fibrosis

(2008) M Edward et al.   JOURNAL OF PATHOLOGY

Risk of Nephrogenic Systemic Fibrosis: Evaluation of Gadolinium Chelate Contrast Agents at Four American Universities

(2008) Rebecca Wertman et al.   RADIOLOGY